Developer docs
API playgroundTry for free, no card

Search company profiles

NOVIOSENSE

Full company profile

uuid000b6eh

Namestring
NOVIOSENSE
Legal namestring
NovioSense BV
Websiteurl
noviosense.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

NovioSense BV is a clinical-stage medical device company founded in 2012 and headquartered at the NovioTech Campus in Nijmegen, Netherlands. The company is developing a non-invasive tear glucose sensor designed to replace the conventional finger-prick blood glucose test for diabetic patients. The device is a flexible spring-like insert (less than 2 cm in length, 1.5 mm in diameter) placed in the inferior conjunctival fornix of the lower eyelid, where it continuously measures glucose in basal tear fluid via an enzymatic glucose oxidase reaction, producing an electrical current that is read out through NFC wireless communication to a smartphone or dedicated reader.

The underlying technology integrates proprietary components: a soft polysaccharide-based hydrogel coating for comfortable extended wear, low-power ASIC chips co-developed with Fraunhofer IMS, and a European Patent for the core biosensor. Clinical development reached Technology Readiness Level 6-7, with Phase 2 results (October 2018) in six Type 1 diabetic patients demonstrating consensus error grid-validated correlation between tear and blood glucose, and a follow-on 24-patient validation study in progress. The platform has been extended beyond diabetes into sports injury prevention sensors via a 2017 NWO Perspectief partnership with TUDelft and Adidas.

The business model is pre-commercial hardware sales to healthcare providers (diabetes clinics and endocrinologists) for prescription to Type 1 and Type 2 diabetic patients, with a complementary direct-to-patient channel via NFC-enabled smartphones. Revenue has not been disclosed; the company is venture-backed (four seed rounds 2012-2016, plus Health Innovations, PPM Oost, NovioTech BV, Fraunhofer-Gesellschaft, Fraunhofer Venture, and Topfonds Gelderland as investors) and supplemented by non-dilutive European grants including a €3M Horizon 2020 Marie Curie award, a €6M NWO Perspectief program, and a €1.6M InterReg subsidy. Market introduction was targeted for Q1 2020 subject to regulatory approval, with the company continuing to seek strategic partners and risk capital to accelerate clinical validation and commercial launch.

Short descriptiontext

NovioSense BV is a clinical-stage Dutch medical device company developing a non-invasive tear glucose sensor that sits in the lower eyelid, using enzymatic biosensing and NFC wireless communication to provide continuous glucose monitoring for Type 1 and Type 2 diabetic patients as a replacement for finger-prick testing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNijmegen, Netherlands
HQ citystring
Nijmegen
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
continuous glucose monitoring, non-invasive biosensors, tear glucose sensor, diabetes monitoring devices, ophthalmic medical sensors
Industry3 codes
PRIMARYHLAHAHAG
Blood Glucose Monitoring (BGM) Meters & Test Strips
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLAHAJAF
Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Continuous Glucose Monitoring Devices
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Tear Glucose Sensor Device Sales
TypeHardware Sales
Description

NovioSense will generate revenue through sale of non-invasive glucose monitoring devices for Type 1 and Type 2 diabetic patients. The device will be compatible with NFC-enabled smartphones as dedicated reader system.

noviosense.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NovioSense develops a non-invasive tear glucose sensor: a small flexible spring-like device (less than 2 cm long, 1.5 mm diameter) coated with soft hydrogel that sits in the lower eyelid to continuously measure glucose levels in tear fluid. The device uses glucose-oxidase enzymatic detection and wireless NFC communication to enable pain-free glucose monitoring for Type 1 and Type 2 diabetic patients, transmitting readings to NFC-enabled smartphones or a dedicated reader system.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 2 clinical trial demonstrated clinically relevant accuracy correlation between tear glucose and blood glucose in Type 1 diabetic patients
+2 more records
Product overview1 text field

NovioSense is a single-product medical device company offering the NovioSense Glucose Sensor—a non-invasive tear glucose monitoring device designed to replace the traditional finger prick for diabetics. The core product is a flexible spring-like sensor worn under the lower eyelid that continuously measures glucose levels in tear fluid using enzymatic detection, with data readout via NFC-enabled smartphones or a dedicated reader system. The device is coated with a proprietary soft hydrogel layer for comfort during extended wear (targeting at least 2 weeks per sensor).

Product and service1 record
1NovioSense Glucose Sensor
CategoryContinuous Glucose Monitoring Devices
Description

A non-invasive tear glucose sensor: a small, flexible, spring-like device (less than 2 cm long, 1.5 mm in diameter) coated with a soft hydrogel layer that sits in the lower eyelid (inferior conjunctival fornix) to continuously measure glucose in tear fluid. It uses glucose-oxidase enzymatic detection, is wirelessly powered, and transmits data via NFC to a smartphone or dedicated reader, providing pain-free continuous and on-demand glucose monitoring for Type 1 (primary) and Type 2 (secondary) diabetic patients.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2017-11-01
Description

Lead partner in NWO Perspectief PLatform program developing sensors to prevent sports injuries. TUDelft received €4M NWO grant with €2.2M additional investment from businesses and sports organizations. 4.5 million sports injuries occur annually in the Netherlands costing €5 billion in medical costs.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2017-11-01
Description

Partner in NWO Perspectief PLatform program to develop sensors for sports injury prevention. Adidas provides industry expertise and co-investment of €2.2M alongside other partners including TUDelft and NedCard.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-07-01
Description

Joined forces with Gentag, Mayo Clinic, and Fraunhofer in 2015 for joint development of sensor technologies. Gentag brings expertise in wearable sensor technology and NFC communication.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-07-01
Description

Partnered with NovioSense, Gentag, and Fraunhofer for joint sensor technology development. Mayo Clinic provides clinical expertise and research capabilities for validation of sensor technologies.

5BioGEL ETN (Horizon 2020)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

BioGEL European Training Network funded €3M to educate 14 young scientists developing innovative hydrogel chemistries for biomedical applications. NovioSense participates in developing functional and responsive hydrogels for medical device coatings.

noviosense.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2013-12-01
Description

Co-developed application-specific integrated circuits (ASICs) with Fraunhofer IMS. The ASIC technology developed pushes the boundaries of power consumption and sensitivity for wearable sensors. This partnership is fundamental to the device's wireless measurement capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partner in iTERM Marie Curie Program and InterReg IV A project. Dr. Daniela Wilson serves as assistant professor at Radboud University contributing expertise in bio-organic chemistry.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Partner in NWO Perspectief PLatform program with TUDelft and Adidas for sports injury prevention sensor development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

OneTouch BGM brand now owned by Platinum Equity; competes in the broader glucose self-monitoring market that NovioSense intends to disrupt.

TypeDirect peer
Description

Developer of Eversense, the only long-term implantable CGM. Closely comparable as a smaller player pursuing an alternative glucose-sensing modality and clinical-validation pathway.

TypeBroad incumbent
Description

Specialty diabetes care company (Contour BGM portfolio) and an obvious strategic acquirer or partner for any non-invasive glucose monitoring entrant.

TypeDirect peer
Description

Market-leading continuous glucose monitor (GCM) manufacturer whose interstitial-fluid CGM systems (G6, G7) are the primary incumbent NovioSense would compete with in non-invasive glucose monitoring.

TypeBroad incumbent
Description

Operates a broad diabetes franchise including insulin pumps, Guardian CGM, and closed-loop systems. Overlaps with NovioSense in CGM and potential closed-loop integration with insulin pumps.

TypeBroad incumbent
Description

Major diabetes care incumbent offering Accu-Chek BGM systems and increasingly digital/monitoring solutions. Comparable as a large player operating in the glucose self-monitoring category NovioSense targets.

TypeEmerging player
Description

Israeli developer of non-invasive glucose monitoring devices using optical signal processing. Comparable emerging peer in the non-invasive glucose monitoring space.

TypeDirect peer
Description

Maker of FreeStyle Libre, the dominant factory-calibrated flash glucose monitor. Direct overlap with NovioSense in the continuous glucose monitoring category for diabetic patients.

9Integrity Applications
TypeEmerging player
Description

Developer of GlucoTrack, a non-invasive ear-clip glucose monitor. Direct emerging peer pursuing the same non-invasive CGM opportunity NovioSense targets.

TypeOthers
Description

European diabetes care distributor and NovioSense supervisory board member via Marco Verhofstadt. Direct channel/distribution partner and natural route to EU commercialization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NOVIOSENSE

Continuous Glucose Monitoring Devicesnoviosense.com

NovioSense BV is a clinical-stage Dutch medical device company developing a non-invasive tear glucose sensor that sits in the lower eyelid, using enzymatic biosensing and NFC wireless communication to provide continuous glucose monitoring for Type 1 and Type 2 diabetic patients as a replacement for finger-prick testing.

What NOVIOSENSE does

NovioSense BV is a clinical-stage medical device company founded in 2012 and headquartered at the NovioTech Campus in Nijmegen, Netherlands. The company is developing a non-invasive tear glucose sensor designed to replace the conventional finger-prick blood glucose test for diabetic patients. The device is a flexible spring-like insert (less than 2 cm in length, 1.5 mm in diameter) placed in the inferior conjunctival fornix of the lower eyelid, where it continuously measures glucose in basal tear fluid via an enzymatic glucose oxidase reaction, producing an electrical current that is read out through NFC wireless communication to a smartphone or dedicated reader.

The underlying technology integrates proprietary components: a soft polysaccharide-based hydrogel coating for comfortable extended wear, low-power ASIC chips co-developed with Fraunhofer IMS, and a European Patent for the core biosensor. Clinical development reached Technology Readiness Level 6-7, with Phase 2 results (October 2018) in six Type 1 diabetic patients demonstrating consensus error grid-validated correlation between tear and blood glucose, and a follow-on 24-patient validation study in progress. The platform has been extended beyond diabetes into sports injury prevention sensors via a 2017 NWO Perspectief partnership with TUDelft and Adidas.

The business model is pre-commercial hardware sales to healthcare providers (diabetes clinics and endocrinologists) for prescription to Type 1 and Type 2 diabetic patients, with a complementary direct-to-patient channel via NFC-enabled smartphones. Revenue has not been disclosed; the company is venture-backed (four seed rounds 2012-2016, plus Health Innovations, PPM Oost, NovioTech BV, Fraunhofer-Gesellschaft, Fraunhofer Venture, and Topfonds Gelderland as investors) and supplemented by non-dilutive European grants including a €3M Horizon 2020 Marie Curie award, a €6M NWO Perspectief program, and a €1.6M InterReg subsidy. Market introduction was targeted for Q1 2020 subject to regulatory approval, with the company continuing to seek strategic partners and risk capital to accelerate clinical validation and commercial launch.

NOVIOSENSE firmographics

Firmographics
Name
NOVIOSENSE
Legal name
NovioSense BV
Website
https://noviosense.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
NovioSense BV is a clinical-stage Dutch medical device company developing a non-invasive tear glucose sensor that sits in the lower eyelid, using enzymatic biosensing and NFC wireless communication to provide continuous glucose monitoring for Type 1 and Type 2 diabetic patients as a replacement for finger-prick testing.
Ownership category
akta.pro rank

NOVIOSENSE industry classification

Industry
Product category
Continuous Glucose Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAHAG
Blood Glucose Monitoring (BGM) Meters & Test Strips
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLAHAJAF
Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Continuous glucose monitoring
  • Non-invasive biosensors
  • Tear glucose sensor
  • Diabetes monitoring devices
  • Ophthalmic medical sensors

Where NOVIOSENSE is headquartered

Location

Headquarters

HQ city
Nijmegen
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

NOVIOSENSE business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Tear Glucose Sensor Device Sales: NovioSense will generate revenue through sale of non-invasive glucose monitoring devices for Type 1 and Type 2 diabetic patients. The device will be compatible with NFC-enabled smartphones as dedicated reader system.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

NOVIOSENSE product offering

Product offering

Core offering

NovioSense develops a non-invasive tear glucose sensor: a small flexible spring-like device (less than 2 cm long, 1.5 mm diameter) coated with soft hydrogel that sits in the lower eyelid to continuously measure glucose levels in tear fluid. The device uses glucose-oxidase enzymatic detection and wireless NFC communication to enable pain-free glucose monitoring for Type 1 and Type 2 diabetic patients, transmitting readings to NFC-enabled smartphones or a dedicated reader system.

Product overview

NovioSense is a single-product medical device company offering the NovioSense Glucose Sensor—a non-invasive tear glucose monitoring device designed to replace the traditional finger prick for diabetics. The core product is a flexible spring-like sensor worn under the lower eyelid that continuously measures glucose levels in tear fluid using enzymatic detection, with data readout via NFC-enabled smartphones or a dedicated reader system. The device is coated with a proprietary soft hydrogel layer for comfort during extended wear (targeting at least 2 weeks per sensor).

Differentiator

Problem solved

Functional benefit

Products and services

  • NovioSense Glucose Sensor A non-invasive tear glucose sensor: a small, flexible, spring-like device (less than 2 cm long, 1.5 mm in diameter) coated with a soft hydrogel layer that sits in the lower eyelid (inferior conjunctival fornix) to continuously measure glucose in tear fluid. It uses glucose-oxidase enzymatic detection, is wirelessly powered, and transmits data via NFC to a smartphone or dedicated reader, providing pain-free continuous and on-demand glucose monitoring for Type 1 (primary) and Type 2 (secondary) diabetic patients.

Quantifiable outcome

  • Phase 2 clinical trial demonstrated clinically relevant accuracy correlation between tear glucose and blood glucose in Type 1 diabetic patients
  • +2 more outcomes

Companies that use NOVIOSENSE

Customer profile

Segments2 records

Ideal customer profiles2 records

NOVIOSENSE technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

NOVIOSENSE partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered major and core.

  • TUDelft (Delft University of Technology)majorStrategic or Co-development Partner · 1 November 2017Lead partner in NWO Perspectief PLatform program developing sensors to prevent sports injuries. TUDelft received €4M NWO grant with €2.2M additional investment from businesses and sports organizations. 4.5 million sports injuries occur annually in the Netherlands costing €5 billion in medical costs.
  • AdidasmajorStrategic or Co-development Partner · 1 November 2017Partner in NWO Perspectief PLatform program to develop sensors for sports injury prevention. Adidas provides industry expertise and co-investment of €2.2M alongside other partners including TUDelft and NedCard.
  • GentagcoreStrategic or Co-development Partner · 1 July 2015Joined forces with Gentag, Mayo Clinic, and Fraunhofer in 2015 for joint development of sensor technologies. Gentag brings expertise in wearable sensor technology and NFC communication.
  • Mayo CliniccoreStrategic or Co-development Partner · 1 July 2015Partnered with NovioSense, Gentag, and Fraunhofer for joint sensor technology development. Mayo Clinic provides clinical expertise and research capabilities for validation of sensor technologies.
  • BioGEL ETN (Horizon 2020)majorStrategic or Co-development Partner · 1 January 2015BioGEL European Training Network funded €3M to educate 14 young scientists developing innovative hydrogel chemistries for biomedical applications. NovioSense participates in developing functional and responsive hydrogels for medical device coatings.
  • Fraunhofer IMScoreTechnology or Integration · 1 December 2013Co-developed application-specific integrated circuits (ASICs) with Fraunhofer IMS. The ASIC technology developed pushes the boundaries of power consumption and sensitivity for wearable sensors. This partnership is fundamental to the device's wireless measurement capabilities.
  • Radboud UniversitycoreStrategic or Co-development PartnerResearch partner in iTERM Marie Curie Program and InterReg IV A project. Dr. Daniela Wilson serves as assistant professor at Radboud University contributing expertise in bio-organic chemistry.
  • NedCardmajorStrategic or Co-development PartnerPartner in NWO Perspectief PLatform program with TUDelft and Adidas for sports injury prevention sensor development.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

NOVIOSENSE competitors and assessment

Company assessment

Broad incumbents

  • LifeScan: OneTouch BGM brand now owned by Platinum Equity; competes in the broader glucose self-monitoring market that NovioSense intends to disrupt.
  • Ascensia Diabetes Care: Specialty diabetes care company (Contour BGM portfolio) and an obvious strategic acquirer or partner for any non-invasive glucose monitoring entrant.
  • Medtronic Diabetes: Operates a broad diabetes franchise including insulin pumps, Guardian CGM, and closed-loop systems. Overlaps with NovioSense in CGM and potential closed-loop integration with insulin pumps.
  • Roche Diabetes Care: Major diabetes care incumbent offering Accu-Chek BGM systems and increasingly digital/monitoring solutions. Comparable as a large player operating in the glucose self-monitoring category NovioSense targets.

Direct peers

  • Senseonics Holdings: Developer of Eversense, the only long-term implantable CGM. Closely comparable as a smaller player pursuing an alternative glucose-sensing modality and clinical-validation pathway.
  • Dexcom: Market-leading continuous glucose monitor (GCM) manufacturer whose interstitial-fluid CGM systems (G6, G7) are the primary incumbent NovioSense would compete with in non-invasive glucose monitoring.
  • Abbott Diabetes Care: Maker of FreeStyle Libre, the dominant factory-calibrated flash glucose monitor. Direct overlap with NovioSense in the continuous glucose monitoring category for diabetic patients.

Emerging players

  • Cnoga Medical: Israeli developer of non-invasive glucose monitoring devices using optical signal processing. Comparable emerging peer in the non-invasive glucose monitoring space.
  • Integrity Applications: Developer of GlucoTrack, a non-invasive ear-clip glucose monitor. Direct emerging peer pursuing the same non-invasive CGM opportunity NovioSense targets.

Others

  • Mediq: European diabetes care distributor and NovioSense supervisory board member via Marco Verhofstadt. Direct channel/distribution partner and natural route to EU commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

NOVIOSENSE social profiles

Digital presence

NOVIOSENSE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NOVIOSENSE leadership team

Management profile

Number of profiles

Profiles5 records

NOVIOSENSE funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NOVIOSENSE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NOVIOSENSE

What does NOVIOSENSE do?

NovioSense develops a non-invasive tear glucose sensor: a small flexible spring-like device (less than 2 cm long, 1.5 mm diameter) coated with soft hydrogel that sits in the lower eyelid to continuously measure glucose levels in tear fluid. The device uses glucose-oxidase enzymatic detection and wireless NFC communication to enable pain-free glucose monitoring for Type 1 and Type 2 diabetic patients, transmitting readings to NFC-enabled smartphones or a dedicated reader system.

Is NOVIOSENSE a public or private company?

NOVIOSENSE is a private company. It is classified as venture growth investor backed and is currently operating.

When was NOVIOSENSE founded?

NOVIOSENSE was founded in 2012. It employs 1 to 10 people.

Where is NOVIOSENSE based?

NOVIOSENSE is headquartered in Nijmegen, Netherlands, in the Europe region.

How does NOVIOSENSE make money?

One revenue line is on record: tear Glucose Sensor Device Sales.

Who are NOVIOSENSE's main competitors?

Broad incumbents on record are LifeScan, Ascensia Diabetes Care, Medtronic Diabetes and Roche Diabetes Care. Direct peers are Senseonics Holdings, Dexcom and Abbott Diabetes Care. Emerging players are Cnoga Medical and Integrity Applications. Mediq is listed as an others.

Does NOVIOSENSE have an API?

No public API is recorded for NOVIOSENSE.

What industry is NOVIOSENSE in?

NOVIOSENSE's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips, with a secondary code of CRACAQAE, Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales